Join to View Full Profile
200 Hawkins DrIowa City, IA 52242
Phone+1 319-356-2353
Fax+1 319-353-8383
Dr. Burkard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mark Burkard is an oncology specialist based in Iowa City, IA, with subspecialties in breast cancer and cancer genetics/cancer risk assessment. He completed his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center and his residency in internal medicine at New York Presbyterian Hospital. He obtained his medical degree from the University of Rochester School of Medicine and Dentistry. His experience includes neoplasm staging, and he has contributed to research with several publications, including studies on breast cancer and super-resolution microscopy. Dr. Burkard has also been involved in clinical trials related to cancer treatment and has received recognition such as the CMS Meaningful Use Stage 1 Certification from Epic Systems Corporation.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2004
University of Rochester School of Medicine and DentistryClass of 2002
Certifications & Licensure
IA State Medical License 2024 - 2025
WI State Medical License 2008 - 2025
NY State Medical License 2003 - 2008
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Dec 10
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer Start of enrollment: 2010 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers.Sneha Phadke, Kathy D Miller, Ami Shah, Oana C Danciu, Yi Chen
Breast Cancer Research and Treatment. 2025-06-05 - Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8T Cells in Breast Cancer.Philip B Emmerich, Tonela Qyli, Katherine A Johnson, Somak Chaudhuri, Kristen M Clark
Cancers. 2025-04-25 - Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity.Jeremy D Kratz, Shujah Rehman, Katherine A Johnson, Amani A Gillette, Aishwarya Sunil
Scientific Reports. 2025-04-09
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
Iowa Has the Fastest Growing Rates of Cancer in the U.S. What’s Being Done to Fight It?May 11th, 2025- Iowa Maintains Fastest-Growing Cancer Rate as Survivor Numbers GrowFebruary 25th, 2025
- Big Cancer Practice Acquisition Reflects Changing Oncology LandscapeOctober 25th, 2024
- Join now to see all
Grant Support
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Mechanisms of paclitaxel sensitivity and resistanceUNIVERSITY OF WISCONSIN-MADISON2024–2029
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Regional differences in guideline-concordant cancer care and outcomes among American Indian Alaska Native peopleUNIVERSITY OF IOWA2024–2026
- Regional differences in guideline-concordant cancer care and outcomes among American Indian Alaska Native peopleUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Preclinical models of serous endometrial cancer from diverse patient populationsUNIVERSITY OF IOWA2024–2026
- Cancer Center Support GrantUNIVERSITY OF IOWA2000–2026
- Cancer Center Support GrantUNIVERSITY OF IOWA2000–2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
